Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
5.68
+0.05 (0.89%)
At close: Oct 29, 2024, 4:00 PM
5.73
+0.05 (0.88%)
After-hours: Oct 29, 2024, 5:38 PM EDT

Company Description

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.

The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.

Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc.
Rezolute logo
Country United States
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Nevan Elam

Contact Details

Address:
275 Shoreline Drive, Suite 500
Redwood City, California 94065
United States
Phone 650 206 4507
Website rezolutebio.com

Stock Details

Ticker Symbol RZLT
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001509261
CUSIP Number 76200L309
ISIN Number US76200L3096
Employer ID 27-3440894
SIC Code 2834

Key Executives

Name Position
Dr. Davelyn Eaves Hood M.B.A., M.D. Director and Head of Scientific and Patient Affairs
Michael R. Deperro Senior Vice President and Head of Corporate Development
Michael Covarrubias Senior Vice President and Head of Program & Portfolio Management
Chris Milks Vice President and Head of Finance
Dr. Raj Agrawal M.D. Vice President and Head of Ophthalmological Clinical Development
Robyn Sweinhart Vice President and Head of Quality
Erin O'Boyle Senior Vice President and Head of Clinical Operations
Susan Stewart J.D., L.L.M. Chief Regulatory Officer

Latest SEC Filings

Date Type Title
Oct 21, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 21, 2024 DEF 14A Other definitive proxy statements
Oct 10, 2024 PRE 14A Other preliminary proxy statements
Sep 19, 2024 10-K Annual Report
Sep 19, 2024 8-K Current Report
Sep 9, 2024 8-K Current Report
Aug 14, 2024 EFFECT Notice of Effectiveness
Aug 12, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933
Aug 9, 2024 UPLOAD Filing
Aug 5, 2024 S-3 Registration statement under Securities Act of 1933